Issue Date: January 1, 2018
Roche buys cancer drugmaker Ignyta
Swiss drug giant Roche will expand its oncology pipeline with a $1.7 billion purchase of the San Diego-based drugmaker Ignyta. The deal is part of a growing trend to design cancer drugs that target tumors with particular genetic mutations, as opposed to a particular tissue. Ignyta’s lead cancer compound, entrectinib, is a small-molecule tyrosine kinase inhibitor. The firm has three other small-molecule programs for cancer, including one compound the company says could boost the innate immune response to tumors.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society